Highlights

  • Profusa shares fell 16.36% to USD 0.4600 on November 12, with approximately 5.13 million shares traded.
  • The company received audited 2024 and 2025 financial statements for proposed Acquisition target G3 Vision Labs.
  • G3 reported combined 2025 Revenue of USD 108 million and adjusted EBITDA of USD 5 million.
  • Profusa said it had regained compliance with Nasdaq listing standards while progressing its Lumee Oxygen Platform.

Profusa Inc. (NASDAQ:PFSA) declined 16.36% to USD 0.4600 on November 12, 2026, with around 5.13 million shares traded. That morning, the company reported additional progress toward satisfying conditions attached to its option to acquire G3 Vision Labs. The announcement moves the focus toward transaction documentation, financing and the potential combination of two different healthcare capabilities. Profusa develops biosensor technologies intended to measure physiological signals, while the proposed G3 combination is positioned around diagnostics. The transaction has not yet become a completed acquisition, and the November price fall cannot establish the market's precise reasoning.

Biosensor technology remains a development priority

Profusa works on sensor platforms intended to provide ongoing measurements from the body. Its Lumee Oxygen Platform is one of the company's identified technologies, and management has been progressing work toward a CE mark. Regulatory milestones matter because product development and commercial authorization involve different requirements. The healthcare technology sector can also Demand substantial spending on validation, production systems and clinical use. For Profusa, the commercial potential of a biosensor platform depends on the quality of its data, regulatory clearance where required and the ability to reach customers through suitable distribution or clinical settings.

G3 financial delivery clears one transaction step

On November 12, Profusa announced receipt of G3's audited consolidated financial statements for 2024 and 2025 and reviewed unaudited results for the six months ended June 30, 2026. The company said the combined G3 Business recorded USD 108 million in revenue and USD 5 million in adjusted EBITDA during 2025, alongside a net loss of USD 2.4 million. These are historical results associated with the proposed acquisition target, not revenue already earned by Profusa. The existing option gives Profusa a right, but not an obligation, to acquire G3 subject to agreed conditions.

Capital steps and Nasdaq compliance support planning

Profusa also reported having entered agreements to exchange USD 10.7 million of Debt and liabilities into a new class of non-voting convertible preferred stock. Conversion into common stock would be subject to Shareholder approval under the announced structure. The company borrowed another USD 0.7 million in October for near-term working capital. It additionally highlighted a September Nasdaq compliance letter confirming compliance with specified minimum bid-price and stockholders' Equity rules. These developments affect the financing and listing framework around Profusa's plans, but they do not resolve every condition required for an acquisition closing.

Closing terms and product approvals remain pivotal

Management indicated an objective of closing the G3 transaction by year-end, subject to remaining steps. Important forthcoming developments include any exercise of the acquisition option, definitive closing disclosures, financing arrangements and progress on the Lumee Oxygen Platform's CE mark process. Profusa's future business mix could change materially if the transaction is completed. Until then, revenue expectations for a combined diagnostics company should be distinguished from Profusa's existing operations. The share-price decline makes the stock's Volatility visible, while the next corporate milestones are contractual and regulatory.

Profusa shares closed at USD 0.4600 on November 12, 2026, down 16.36%, with approximately 5.13 million shares traded.